Overview

• INmune Bio Q3 net loss narrows to $6.5 mln from $12.1 mln year-over-year

• Operating expenses for Q3 decreased to $7.4 mln from $12.3 mln year-over-year

• Company announces leadership changes with David Moss as new CEO

Outlook

• Company plans to file CORDStrom™ MAA submission mid-2026

• Company expects End of Phase 2 meeting for XPro™ in Q1 2026

• Final data on INKmune CARE-PC trial expected in Q4 2026

Result Drivers

• CORDStrom MANUFACTURING - Successful completion of first two commercial pilot-scale manufacturing runs in preparation for regulatory filings

• INKmune TRIAL PROGRESS - CARE-PC trial met primary endpoint and two secondary endpoints, indicating NK cell proliferation and function

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 74% above its October 29 closing price of $1.82

Press Release: ID:nGNX6NVPqd

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)